Expanded controlled substance capabilities enables Particle Sciences to develop and manufacture Schedule I–V drugs.
Particle Sciences, a Lubrizol LifeSciences company and pharmaceutical contract development and manufacturing organization, announced on May 23, 2019 that it received Drug Enforcement Administration (DEA) registration to be an authorized manufacturer of Schedule I substances.
The expanded registration will allow the company to conduct analytical testing, development, and manufacturing of cannabis-derived materials to be used in pharmaceutical applications for medically justified, legal uses in the United States.
The company reports existing capabilities to develop and manufacture Schedule II–V controlled drug products at its facility in Bethlehem, PA. Previously, the company worked on projects ranging from a novel nasal delivery system for diazepam to long-acting buprenorphine dosage forms.
“Particle Sciences has built a solid reputation and specialized expertise in controlled substances as a result of our team’s work in complex formulations with substances in Schedules II–V,” said Robert Lee, president of Particle Sciences in a press statement announcing the approval. “A high level of ethical standards and water-tight controls/processes including accurate documentation are essential to carry out controlled substances work and these are already firmly ingrained in our day-to-day operations.”
Source: Particle Sciences
Market Demands and Emerging Technologies Shape Outsourcing Models
June 5th 2025Trends in certain forms of drug delivery, as well as the emergence of artificial intelligence, are playing roles in evolving the nature of partnerships, but there are new types of partnerships gaining steam as well.
Guidance on Quality Culture Standards
June 3rd 2025Matt Cushing, VP of Quality and Science, Nelson Labs, and Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs Company, discuss PDA/ANSI Standard 06-2025: Assessment of Quality Culture Guidance Documents, Models, and Tools, which was published in February 2025.